TORONTO--(BUSINESS WIRE)--SQI Diagnostics Inc. (“SQI” or the “Company”) (TSX-V: SQD), a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that it has realigned its business to streamline its product development portfolio and to focus on revenue generation from its Diagnostic Tools and Services business. As part of this realignment the Company has reduced its workforce by 14 positions leaving a total workforce of 36 employees. The reduction in workforce and realignment of its operations and R&D activities is expected to result in incremental cost savings of approximately $3.5 million annually with approximately half of the reductions coming from workforce reductions.
